Aug 26, 2020
Agenus Announces ESMO Oral Presentation of Two Clinical Trials of Balstilimab Alone and in Combination with Zalifrelimab in Recurrent or Metastatic Cervical Cancer
Aug 06, 2020
Agenus Provides R&D Update & Second Quarter Financial Report
Aug 04, 2020
Agenus to Present on Targeting Myeloid Cells in Tumor Microenvironment at the William Blair Biotech Focus 2020 Conference
Jul 29, 2020
Agenus R&D update & Second Quarter Earnings Report
Jul 28, 2020
Agenus Receives $35M In Immuno-Oncology Transaction with Betta Pharmaceuticals
Jul 21, 2020
Agenus To Participate in a Panel on Cell Therapy for Infectious Diseases at the B. Riley Virtual Infectious Disease Summit
Jun 22, 2020
Agenus Cell Therapy and Checkpoint Antibody Combinations Show Curative Preclinical Efficacy at AACR 2020
Jun 22, 2020
Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China
Jun 17, 2020
Agenus and AgenTus to Participate in a Panel Presentation on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference
Jun 16, 2020
Agenus Announces Virtual Annual Shareholders Meeting
Jun 02, 2020
FDA Clears IND for iNKT Cells to Treat COVID-19 Patients
May 14, 2020
Agenus NextGen CTLA-4 Antibody (AGEN1181) Data to be Presented at ASCO
May 13, 2020
FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy
May 07, 2020
Agenus First Quarter Results and Update
Apr 28, 2020
Agenus to Report First Quarter 2020 Financial Results on May 7, 2020 and Host Conference Call and Webcast
Mar 12, 2020
Agenus Receives Fast Track Designation for Balstilimab & Zalifrelimab in Advanced Cervical Cancer
Mar 10, 2020
First QS-21 Royalty Payment Due to Agenus is Triggered
Mar 03, 2020
Agenus to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 with Conference Call and Webcast
Feb 20, 2020
Agenus Announces Positive Interim Data from Balstilimab and Zalifrelimab Clinical Trials in Second-Line Cervical Cancer
Jan 09, 2020
Agenus Announces the Appointment of Dr. Jennifer Buell to the position of President and COO